Home / Companies / KalVista Pharmaceuticals, Inc. / 3 Oct 2024
KalVista Pharmaceuticals, Inc.: meeting of 3 Oct 2024
Votes reported on Form N-PX, item by item
191 Form N-PX filers reported votes at the KalVista Pharmaceuticals, Inc. meeting of 3 Oct 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 69.9% of reported votes for; 40 filers withheld from or voted against at least one nominee.
240 vote records from 62 filers. 3 of the 61 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
273 vote records from 190 filers. 50 of the 184 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
120 vote records from 62 filers. 0 of the 61 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | Split or no vote | Against * | For |
| State Street and SPDR | Split or no vote | For | For |
| American Century | Split or no vote | Against * | For |
| Invesco | No report | Against * | No report |
| Equitable | For | For | For |
| Charles Schwab | Split or no vote | For | For |
| Nuveen and TIAA | Split or no vote | For | For |
| ProShares and ProFunds | Split or no vote | For | For |
| John Hancock and Manulife | Split or no vote | For | For |
| Morgan Stanley, Eaton Vance and Calvert | For | For | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | No report | For | No report |
| PGIM and Prudential | Against * | For | For |
| Jackson National funds | Split or no vote | Against * | For |
| Northern Trust and FlexShares | For | For | For |
| SEI | Split or no vote | Against * | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | Split or no vote | For | For |
| Voya | Split or no vote | For | For |
| Russell Investments | For | Against * | For |
| Nationwide | Split or no vote | Against * | For |
| Victory Capital | Split or no vote | For | For |
| Brighthouse Funds | Split or no vote | For | For |
| Guggenheim and Rydex | Split or no vote | For | For |
| BNY Mellon | No report | Against * | No report |
| Principal | Against * | For | For |
| Capital Group and American Funds | For | Against * | For |
| Pacific Life funds | For | For | For |
| Global X | Split or no vote | Against * | For |
| AllianceBernstein | No report | For | No report |
| DWS | Split or no vote | For | For |
| Neuberger Berman | No report | Against * | No report |
| Natixis and Loomis Sayles | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the KalVista Pharmaceuticals, Inc. meeting?
191 Form N-PX filers reported votes at the meeting of 3 Oct 2024. On say-on-pay, 50 of 184 voted against management (27.2%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by KalVista Pharmaceuticals, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for KalVista Pharmaceuticals, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing KalVista Pharmaceuticals, Inc. with a meeting date within three days of 3 Oct 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.